A new study on mice published in Nature Neuroscience finds that fingolimod (Novartis brand name Gilenya) a first-in-class sphingosine-1-phosphate-receptor modulator currently used in treating persons with severe relapsing remitting MS, may also have therapeutic value in treating Post Traumatic Stress Disorder (PTSD). The Nature Neuroscience study is titled…
Gilenya
Recommended Posts
- I’m not letting MS stop me from starting an outdoor backyard garden of my own
- AAN 2026: GA Depot may help stabilize disability in RMS and PPMS
- AAN 2026: Top-tier MS drugs out of reach for many on Medicaid
- New method confirms positive clinical trial results for MS drug Tecfidera
- AAN 2026: AI-powered MS blood test sees growing use in real-world care